{"nctId":"NCT01900704","briefTitle":"Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4","startDateStruct":{"date":"2013-08"},"conditions":["Nocturia"],"count":810,"armGroups":[{"label":"SER120 750 ng","type":"EXPERIMENTAL","interventionNames":["Drug: SER120 750 ng"]},{"label":"SER120 1500 ng","type":"EXPERIMENTAL","interventionNames":["Drug: SER120 1500 ng"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"SER120 750 ng","otherNames":[]},{"name":"SER120 1500 ng","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female 50 years or older\n* Nocturia of 6 or more months duration averaging greater than 2 nocturic episodes per night\n\nExclusion Criteria:\n\n* CHF\n* Diabetis Insipidus\n* Renal insufficiency\n* Hepatic insufficiency\n* Incontinence\n* Illnesses requiring systemic steroids\n* Malignancy within the past 5 years\n* Sleep apnea\n* Nephrotic syndrome\n* Unexplained pelvic mass\n* Urinary bladder neurological dysfunction\n* Urinary bladder surgery or radiotherapy\n* Pregnant or breast feeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","maximumAge":"95 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Nocturic Episodes at the End of Treatment Compare to Prior to Treatment","description":"Change was calculated based on the number of mean nocturic episodes per night between baseline through week 12","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"0.06"},{"groupId":"OG001","value":"-1.5","spread":"0.06"},{"groupId":"OG002","value":"-1.2","spread":"0.06"}]}]}]},{"type":"PRIMARY","title":"Percent of Participants With Equal of Greater Than 50% Reduction in Mean Nocturic Episodes","description":"Percent of participants with equal of greater than 50% reduction in mean nocturic episodes over the twelve week period","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"121","spread":null},{"groupId":"OG002","value":"74","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":266},"commonTop":["Nasal discomfort","Headache","Urinary tract infection"]}}}